Our network

Access no one else has. Measured.

40,000+
verified members
40+
specialties
100+
countries
12+
languages
Depth, by specialty
Primary care · at volumeOncology · 2,000+Cardiology · deepEndocrinology · deepNeurology · deepInternal medicine · deepSurgery · deepFamily medicine · deepRare disease · composed to spec
Reach, by geography
United States · largest single baseEurope · Spain, Portugal + wide coverageLatin America · Spanish-native depthIndia · Hindi, Gujarati + vernacular cellsSoutheast Asia · Philippines hub
The network behind the community

250K → 500K in four years.

The verified network doubled FY2023 → FY2026.

250K
FY23
320K
FY24
410K
FY25
500K
FY26
Specialist-weighted by design.

~72% of the network is specialists, rare-disease physicians and hard-to-reach stakeholders — the inverse of a typical opt-in panel.

Rare & orphan disease · 50,000+Oncology (incl. heme-onc) · 38,000+High-value specialist cells · Neuro, Nephro, Cardio, ImmunoAcademic & teaching-hospital based · ~32%
Where they are.

USA ~39% of the network · EU5 in five of the top eight markets · deep cells across the UK, Japan, Latin America, India and Southeast Asia — 100+ countries in all.

Who’s inside

Bedside to boardroom.

Physicians & specialists · largest cohortNurses & NPsPhysician assistantsPharmacists
Payers & PBMsPharma & biotech professionalsMedTech professionalsResidents in accredited training

One study can span the chain: prescriber → formulary decision-maker → buyer. Same verified community.

Verified is a process, not an adjective.

01
Credential capture
02
OTP
03
Biometric liveness
04
Device & email risk intel
05
Human license QC vs official registries
06
Government-ID + face match

Every member reviewed by our QC team before their first task.

Visit the community → Request the catalogue